These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15584126)

  • 21. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Bell DS
    Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
    [No Abstract]   [Full Text] [Related]  

  • 23. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
    Anselmino M; Malmberg K; Ohrvik J; Rydén L;
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):216-23. PubMed ID: 18391651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myocardial infarction in patients with diabetes mellitus type 2].
    Ochotny R; Piszczek I; Błaszyk K; Poprawski K
    Kardiol Pol; 1988; 31(9):563-8. PubMed ID: 3244232
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a 'low ejection fraction' equivalent?
    Gore MO; Masoudi FA; McGuire DK
    Eur J Heart Fail; 2010 Nov; 12(11):1156-8. PubMed ID: 20965878
    [No Abstract]   [Full Text] [Related]  

  • 27. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for angiotensin receptor blockers in diabetic retinopathy.
    Sjølie AK
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetes mellitus and myocardial infarction: a time to act or a time to wait?
    Fisher BM
    Diabet Med; 1998 Apr; 15(4):275. PubMed ID: 9585390
    [No Abstract]   [Full Text] [Related]  

  • 30. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihypertensive treatments for adults with type 2 diabetes.
    Majumdar SR
    BMJ; 2016 Feb; 352():i560. PubMed ID: 26867645
    [No Abstract]   [Full Text] [Related]  

  • 33. The impact of Type 2 diabetes and microalbuminuria on future cardiovascular events in patients with clinically manifest vascular disease from the Second Manifestations of ARTerial disease (SMART) study.
    Soedamah-Muthu SS; Visseren FL; Algra A; van der Graaf Y;
    Diabet Med; 2008 Jan; 25(1):51-7. PubMed ID: 18199132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.
    Verma S; Leiter LA; Lonn EM; Strauss MH
    Eur Heart J; 2005 Jul; 26(14):1347-9. PubMed ID: 15872030
    [No Abstract]   [Full Text] [Related]  

  • 35. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
    Furberg CD; Psaty BM
    Circulation; 2003 Nov; 108(21):2608-10. PubMed ID: 14638524
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Atherosclerosis. High dosage ACE inhibitor keeps event rate under control].
    MMW Fortschr Med; 2001 Mar; 143(13):53. PubMed ID: 11332025
    [No Abstract]   [Full Text] [Related]  

  • 38. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification.
    Maahs DM; Snell-Bergeon JK; Kinney GL; Wadwa RP; Garg S; Ogden LG; Rewers M
    J Diabetes Complications; 2007; 21(5):273-9. PubMed ID: 17825750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Painful legs, aching heart: Reducing cardiovascular risk in patients with peripheral arterial disease with angiotensin-converting enzyme inhibition.
    Gupta MK; Verma S
    Can J Cardiol; 2005 Feb; 21(2):194-5. PubMed ID: 15729422
    [No Abstract]   [Full Text] [Related]  

  • 40. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.